KSQ-004

N/A

Report date: 2026/04/17 10:36:28

Base Information

Drug NameKSQ-004

Drug Alias NameKSQ-004KSQ-004EXKSQ-004EX eTIL

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9

Mechanisms of ActionT lymphocyte replacementsRegnase-1 inhibitorsSuppressor of cytokine signaling 1 inhibitors

TargetsRegnase-1Suppressor of cytokine signaling 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesKSQ Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center KSQ Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A